Stock comparison
BrainsWay
United Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
BWAY
BrainsWay
Market cap
$592.27M
Sector
Healthcare
UTHR
United Therapeutics
Market cap
$24.13B
Sector
Healthcare
Overall winner
United Therapeutics UTHR
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | BWAY | UTHR | Winner |
|---|---|---|---|
| Warren Buffett | 43D | 71B | UTHR |
| Benjamin Graham | 70D | 76B | UTHR |
| Philip Fisher | 57C | 76B | UTHR |
| Peter Lynch | 52C | 62C | UTHR |
| Joel Greenblatt | 46D | 46D | Tie |
| Charlie Munger | 41D | 64C | UTHR |
| Terry Smith | 52D | 64C | UTHR |
Side-by-side metrics
| Metric | BWAY | UTHR |
|---|---|---|
| Market cap | $592.27M | $24.13B |
| P/E (TTM) | 75.0x | 19.2x |
| EV/EBIT | 123.9x | 15.2x |
| ROIC (TTM) | 5.05% | 18.81% |
| Gross margin | 75.42% | 86.58% |
| Net margin | 13.5% | 40.61% |
| Revenue CAGR 5y | 15.42% | 17.22% |
| EPS CAGR 5y | - | 29.84% |
| Debt / Equity | 0.1x | - |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
BWAY leads on
No clear edges - the other side wins or ties on every measured metric.
UTHR leads on
- Debt / Equity-vs 0.1x+100%
- Market cap$24.13Bvs $592.27M+98%
- EV/EBIT15.2xvs 123.9x+88%
- P/E (TTM)19.2xvs 75.0x+74%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.